Ion Beam Applications SA

Brussels Stock Exchange IBAB.BR

Ion Beam Applications SA Current Liabilities for the year ending December 31, 2023: USD 499.56 M

Ion Beam Applications SA Current Liabilities is USD 499.56 M for the year ending December 31, 2023, a 1.24% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.
  • Ion Beam Applications SA Current Liabilities for the year ending December 31, 2022 was USD 493.43 M, a 24.36% change year over year.
  • Ion Beam Applications SA Current Liabilities for the year ending December 31, 2021 was USD 396.79 M, a 17.81% change year over year.
  • Ion Beam Applications SA Current Liabilities for the year ending December 31, 2020 was USD 336.80 M, a 23.94% change year over year.
  • Ion Beam Applications SA Current Liabilities for the year ending December 31, 2019 was USD 271.74 M, a 0.78% change year over year.
Key data
Date Current Liabilities Total Non-Current Liabilities Shareholders' Equity Long-Term Debt
Market news
Loading...
Brussels Stock Exchange: IBAB.BR

Ion Beam Applications SA

CEO Mr. Olivier Legrain
IPO Date Jan. 4, 2000
Location Belgium
Headquarters 3, Chemin du Cyclotron
Employees 1,943
Sector Health Care
Industries
Description

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for advance research in ConformalFLASH. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Similar companies

BEKB.BR

NV Bekaert SA

USD 33.74

-0.13%

EVS.BR

EVS Broadcast Equipment SA

USD 31.12

0.60%

MELE.BR

Melexis NV

USD 60.03

0.18%

BAR.BR

Barco NV

USD 9.69

0.18%

StockViz Staff

January 16, 2025

Any question? Send us an email